As of 2025-11-16, the EV/EBITDA ratio of Prostatype Genomics AB (PROGEN.ST) is -0.22. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PROGEN.ST's latest enterprise value is 8.45 mil SEK. PROGEN.ST's TTM EBITDA according to its financial statements is -39.18 mil SEK. Dividing these 2 quantities gives us the above PROGEN.ST EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.4x - 17.8x | 11.6x |
| Forward P/E multiples | 15.0x - 17.8x | 16.4x |
| Fair Price | (15.53) - (18.50) | (14.48) |
| Upside | -2787.7% - -3300.6% | -2604.5% |
| Date | EV/EBITDA |
| 2025-11-13 | -0.25 |
| 2025-11-12 | -0.25 |
| 2025-11-11 | -0.24 |
| 2025-11-10 | -0.20 |
| 2025-11-07 | -0.20 |
| 2025-11-06 | -0.17 |
| 2025-11-05 | -0.21 |
| 2025-11-04 | -0.22 |
| 2025-11-03 | -0.23 |
| 2025-10-31 | -0.30 |
| 2025-10-30 | -0.25 |
| 2025-10-29 | -0.25 |
| 2025-10-28 | -0.21 |
| 2025-10-27 | -0.23 |
| 2025-10-24 | -0.28 |
| 2025-10-23 | -0.29 |
| 2025-10-22 | -0.32 |
| 2025-10-21 | -0.33 |
| 2025-10-20 | -0.33 |
| 2025-10-17 | -0.37 |
| 2025-10-16 | -0.37 |
| 2025-10-15 | -0.36 |
| 2025-10-14 | -0.32 |
| 2025-10-13 | -0.33 |
| 2025-10-10 | -0.33 |
| 2025-10-09 | -0.39 |
| 2025-10-08 | -0.29 |
| 2025-10-07 | -0.24 |
| 2025-10-06 | -0.20 |
| 2025-10-03 | -0.19 |
| 2025-10-02 | -0.16 |
| 2025-10-01 | -0.18 |
| 2025-09-30 | -0.21 |
| 2025-09-29 | -0.21 |
| 2025-09-26 | -0.23 |
| 2025-09-25 | -0.22 |
| 2025-09-24 | -0.23 |
| 2025-09-23 | -0.22 |
| 2025-09-22 | -0.21 |
| 2025-09-19 | -0.28 |
| 2025-09-18 | -0.25 |
| 2025-09-17 | -0.30 |
| 2025-09-16 | -0.27 |
| 2025-09-15 | -0.23 |
| 2025-09-12 | -0.19 |
| 2025-09-11 | -0.23 |
| 2025-09-10 | -0.22 |
| 2025-09-09 | -0.21 |
| 2025-09-08 | -0.22 |
| 2025-09-05 | -0.21 |